The global opioid use disorder (OUD) market size was estimated to be USD 3.41 billion in 2023 and is expected to reach at USD 9.81 billion by 2034 with a CAGR of 10.08% during the forecast period 2024-2034. Increasing prevalence of chronic diseases such as cancer, orthopedic diseases, & cardiovascular diseases, surge in number of opioid addicts, rising consideration of buprenorphine patches as an effective treatment mode, growing demand for buprenorphine treatment patches, increasing new product launch, surge in product approval for opioid use disorder drugs, growing funding for opioid overdose awareness programs by government organizations, and rising mergers & acquisitions between major market players are some of the key factors boosting the market growth.
Rising mergers & acquisitions between major market players for the formulations of advanced medications is predicted to boost the market growth during the forecast period. The increasing prevalence of chronic pain worldwide is expected to lead to a rise in prescriptions for painkillers, many of which contain opioids. Unfortunately, as individuals take these opioid-based painkillers and experience relief from their discomfort, the risk of developing dependence or addiction to these drugs also increases. This addiction carries grave consequences, as an opioid overdose can result in death or have long-lasting negative effects on a person's mental and physical well-being, posing significant risks. For instance, in March 2023, Indivior PLC has finalized the acquisition of Opiant Pharmaceutical Inc., including their developmental candidate OPNT003 aimed at treating opioid overdose. This strategic move by Indivior enhances their role in the field of addiction treatment.
By drug, agonist was the highest revenue-grossing segment in the global opioid use disorder (OUD) market in 2023 owing to the increasing prevalence of chronic pain, rising prevalence of opioid abuse, growing geriatric population prone to painful disease, surge in demand for buprenorphine treatment patches, and increasing initiatives by government organizations. For instance, in April 2023, The launch of the Buprenorphine Assistance Pilot Program has been declared by the New York State Department of Health (DOH) and the New York State Office of Addiction Services and Supports (OASAS). This initiative aims to provide financial support for buprenorphine, which is used in the treatment of opioid use disorder (OUD). Additionally, antagonist is predicted to grow at fastest CAGR during the forecast period owing to growing research & development activities on naltrexone drugs by major players and increasing strategic alliances within key market players.
By age group, 19 to 39 was the highest revenue-grossing segment in the global opioid use disorder (OUD) market in 2023 owing to the surge in prevalence of chronic diseases such as cardiovascular diseases, cancer, & orthopedic diseases associated with chronic pain, rising regulatory approvals of novel drugs, and increasing initiatives by market players. For instance, in April 2023, The New York State Department of Health (DOH) and the New York State Office of Addiction Services and Supports (OASAS) have launched the Buprenorphine Assistance Pilot Program, designed to offer financial aid for buprenorphine in the treatment of Opioid Use Disorder (OUD). Additionally, age 60 & over is predicted to grow at fastest CAGR during the forecast period owing to the growing geriatric population and rising prevalence of orthopedic diseases.
By route of administration, intravenous was the highest revenue-grossing segment in the global opioid use disorder (OUD) market in 2023 owing to the growing demand of intravenous route for the treatment of opioids use disorder treatment and increasing approvals by regulatory bodies. For instance, in December 2022, The FDA has approved the re-submission of the New Drug Application (NDA) for Brixadi, an extended-release subcutaneous injection of buprenorphine. This injection is designed for treating moderate to severe opioid use disorder in individuals who have either started treatment with a transmucosal buprenorphine product or are already undergoing buprenorphine treatment. Additionally, oral is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of individuals opting for oral administration of drugs over injection and increasing launch of new therapies.
By distribution channel, hospital pharmacy was the highest revenue-grossing segment in the global opioid use disorder (OUD) market in 2023 owing to the growing number of hospital pharmacy, rising expenditure by government for the development of healthcare infrastructure, surge in prevalence of opioids use disorder, and increasing collaborations within market players. For instance, In March 2022, Collegium Pharmaceutical, Inc. has finalized its purchase of BioDelivery Sciences International Inc. Additionally, online pharmacy is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of patients started using online pharmacies to acquire their drugs and increasing collaborations within market players for the development of digital platforms.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising new product launch, growing product approval for opioids use disorder, surge in prevalence of chronic diseases, and increasing mergers & acquisitions within market players. For instance, in March 2022, Collegium Pharmaceutical Inc. has successfully finalized the acquisition of BioDelivery Sciences International Inc. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing geriatric populations, increasing awareness regarding availability of healthcare services, rising prevalence of chronic diseases, and surge in approvals of novel treatment. For instance, in May 2023, Opvee (nalmefene hydrochloride; Indivior) has received FDA approval for use as an emergency treatment to counteract confirmed or suspected opioid overdoses in individuals aged 12 years and above.
Rising mergers & acquisitions between major market players for the formulations of advanced medications is predicted to boost the market growth during the forecast period. The increasing prevalence of chronic pain worldwide is expected to lead to a rise in prescriptions for painkillers, many of which contain opioids. Unfortunately, as individuals take these opioid-based painkillers and experience relief from their discomfort, the risk of developing dependence or addiction to these drugs also increases. This addiction carries grave consequences, as an opioid overdose can result in death or have long-lasting negative effects on a person's mental and physical well-being, posing significant risks. For instance, in March 2023, Indivior PLC has finalized the acquisition of Opiant Pharmaceutical Inc., including their developmental candidate OPNT003 aimed at treating opioid overdose. This strategic move by Indivior enhances their role in the field of addiction treatment.
By drug, agonist was the highest revenue-grossing segment in the global opioid use disorder (OUD) market in 2023 owing to the increasing prevalence of chronic pain, rising prevalence of opioid abuse, growing geriatric population prone to painful disease, surge in demand for buprenorphine treatment patches, and increasing initiatives by government organizations. For instance, in April 2023, The launch of the Buprenorphine Assistance Pilot Program has been declared by the New York State Department of Health (DOH) and the New York State Office of Addiction Services and Supports (OASAS). This initiative aims to provide financial support for buprenorphine, which is used in the treatment of opioid use disorder (OUD). Additionally, antagonist is predicted to grow at fastest CAGR during the forecast period owing to growing research & development activities on naltrexone drugs by major players and increasing strategic alliances within key market players.
By age group, 19 to 39 was the highest revenue-grossing segment in the global opioid use disorder (OUD) market in 2023 owing to the surge in prevalence of chronic diseases such as cardiovascular diseases, cancer, & orthopedic diseases associated with chronic pain, rising regulatory approvals of novel drugs, and increasing initiatives by market players. For instance, in April 2023, The New York State Department of Health (DOH) and the New York State Office of Addiction Services and Supports (OASAS) have launched the Buprenorphine Assistance Pilot Program, designed to offer financial aid for buprenorphine in the treatment of Opioid Use Disorder (OUD). Additionally, age 60 & over is predicted to grow at fastest CAGR during the forecast period owing to the growing geriatric population and rising prevalence of orthopedic diseases.
By route of administration, intravenous was the highest revenue-grossing segment in the global opioid use disorder (OUD) market in 2023 owing to the growing demand of intravenous route for the treatment of opioids use disorder treatment and increasing approvals by regulatory bodies. For instance, in December 2022, The FDA has approved the re-submission of the New Drug Application (NDA) for Brixadi, an extended-release subcutaneous injection of buprenorphine. This injection is designed for treating moderate to severe opioid use disorder in individuals who have either started treatment with a transmucosal buprenorphine product or are already undergoing buprenorphine treatment. Additionally, oral is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of individuals opting for oral administration of drugs over injection and increasing launch of new therapies.
By distribution channel, hospital pharmacy was the highest revenue-grossing segment in the global opioid use disorder (OUD) market in 2023 owing to the growing number of hospital pharmacy, rising expenditure by government for the development of healthcare infrastructure, surge in prevalence of opioids use disorder, and increasing collaborations within market players. For instance, In March 2022, Collegium Pharmaceutical, Inc. has finalized its purchase of BioDelivery Sciences International Inc. Additionally, online pharmacy is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of patients started using online pharmacies to acquire their drugs and increasing collaborations within market players for the development of digital platforms.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising new product launch, growing product approval for opioids use disorder, surge in prevalence of chronic diseases, and increasing mergers & acquisitions within market players. For instance, in March 2022, Collegium Pharmaceutical Inc. has successfully finalized the acquisition of BioDelivery Sciences International Inc. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing geriatric populations, increasing awareness regarding availability of healthcare services, rising prevalence of chronic diseases, and surge in approvals of novel treatment. For instance, in May 2023, Opvee (nalmefene hydrochloride; Indivior) has received FDA approval for use as an emergency treatment to counteract confirmed or suspected opioid overdoses in individuals aged 12 years and above.
Segmentation: Opioid Use Disorder (OUD) Market Report 2022 - 2033
Opioid Use Disorder (OUD) Market Analysis & Forecast by Drug 2023 - 2034 (Revenue USD Bn)
Agonist
- Buprenorphine
- Methadone
Antagonist
- Naltrexone
Opioid Use Disorder (OUD) Market Analysis & Forecast by Age Group 2023 - 2034 (Revenue USD Bn)
- 19 to 39
- 40 to 59
- Age 60 & Over
Opioid Use Disorder (OUD) Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)
- Intravenous
- Oral
- Sublingual
Opioid Use Disorder (OUD) Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Opioid Use Disorder (OUD) Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Opioid Use Disorder (OUD) Market: Drug Estimates & Trend Analysis
8. Opioid Use Disorder (OUD) Market: Age Group Estimates & Trend Analysis
9. Opioid Use Disorder (OUD) Market: Route of Administration Estimates & Trend Analysis
10. Opioid Use Disorder (OUD) Market: Distribution Channel Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Opioid Use Disorder (OUD) Market
13. Europe Global Opioid Use Disorder (OUD) Market
14. Asia Pacific Global Opioid Use Disorder (OUD) Market
15. Latin America Global Opioid Use Disorder (OUD) Market
16. MEA Global Opioid Use Disorder (OUD) Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Orexo AB
- Viatris Inc
- Reckitt Benckiser Pharmaceuticals Inc
- Titan Pharmaceuticals Inc.
- OREXO AB
- Hikma Pharmaceuticals PLC
- Sandoz
- Biodelivery Sciences International Inc.
- Pear Therapeutics
- NYC Health Hospitals
- Astrazeneca Plc
- Alkermes Inc.
- Indivior PLC
- Camurus
- Dr Reddy Laboratories Ltd
- Braeburn Pharmaceuticals
- Mallinckrodt Pharmaceuticals
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 3.41 Billion |
| Forecasted Market Value ( USD | $ 9.81 Billion |
| Compound Annual Growth Rate | 10.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 17 |
